Flagship Merges Cellarity, Etiome and Empress Into AI Biotech Etcelera

Cambridge venture firm Flagship Pioneering on Thursday, Oct. 29, 2026, launched Etcelera, a Somerville-based drug discovery company formed by merging the platforms of three of its startups: Cellarity, Etiome and Empress Therapeutics. The Etcelera launch combines their lab data with Flagship’s in-house artificial intelligence tools to try to predict which experimental medicines will work in patients before they reach clinical trials.

No new funding was announced with the launch. The three companies had raised a combined $374 million in venture capital before the merger, BioPharma Dive reported, and Etcelera’s CEO said that money will help carry the new company forward. Flagship said Etcelera launches “with continued support from Flagship Pioneering and others.”

The size and shape of the Etcelera merger

The deal is a consolidation inside Flagship’s own portfolio rather than an outside acquisition. Flagship did not disclose a valuation, employee count or the ownership split among the three predecessor companies. The merger took effect with Thursday’s announcement, according to the company’s release.

Etcelera is led by CEO Adrian “Ad” Rawcliffe, a Flagship CEO-partner who spent the past 10 months as CEO of Etiome, Fierce Biotech reported. He was previously CEO of Adaptimmune and earlier worked at GSK. Alec Reynolds, a senior partner at Flagship, is chairman, and Flagship founder and CEO Noubar Afeyan is a co-founder.

One asset is staying out of the new company. Cellarity’s oral sickle cell disease drug candidate, CLY-124, which entered a Phase 1 study in June 2025, is being advanced by a separate, dedicated company, according to Flagship and Fierce Biotech.

What each startup brings

Cellarity, founded in 2017, built an AI foundation model trained on human cell data to read and analyze the state of whole cells. Etiome developed technology that maps how disease processes change over time, to help identify the right stage and the right patients for treatment. Empress Therapeutics contributes an industrialized Perturb-seq platform, which uses single-cell genomics to test how cells respond when genes or chemicals disrupt them, running hundreds or thousands of hypotheses at once.

Flagship said the combined platform draws on more than 20 years of data, including a foundation model trained on data from 150 million cells, and more than 30 proprietary AI prediction models. The company calls its approach “causal intelligence”: working out what actually drives a disease rather than what merely correlates with it.

Pipeline and partnerships

Etcelera starts with programs in three areas: hematology, including preclinical programs in myelofibrosis and essential thrombocythemia; metabolism, including partnered work in metabolic dysfunction-associated steatohepatitis (MASH); and immunology. It keeps a 2022 partnership between Cellarity and Novo Nordisk to find a small-molecule MASH treatment. Rawcliffe told BioPharma Dive that a second alliance with an unnamed large drugmaker is in the works, and he told Fierce Biotech to expect “substantial business development activity” over the next six to 12 months.

The company’s pitch rests on a familiar industry problem. Flagship said about half of drug candidates that reach Phase 2 trials fail, which it attributes to a lack of causal understanding of disease. BioPharma Dive noted that AI drug discovery has drawn heavy private investment in 2026 even as several AI-focused biotechs have struggled in public markets.

Why it matters for the Boston biotech scene

Flagship, founded in 2000, has originated more than 100 ventures, including Cambridge vaccine maker Moderna, and says it has $14 billion of assets under its direction. Rolling three young companies into one is a different move from the usual startup launch, and it comes during a tough year for local biotech employment, covered in our report on Kendall Square biotech layoffs and lab vacancies. Big private money is still flowing to some Massachusetts companies, as in Framingham manufacturer Re:Build’s $2.1 billion raise this week.

Massachusetts’ unemployment rate was 4.3% in September 2026, according to Bureau of Labor Statistics data compiled by FRED. More local startup and company coverage is in the Boston business and economy section.

Reaction

“Each of these foundational platforms has been a pioneer in its own right,” Afeyan said in the announcement. “Yet, the hardest problems in medicine don’t yield to a single approach.” Rawcliffe said: “We can predict where a rocket will land, yet we still can’t predict what a medicine will do in a patient.” Reynolds said the goal is “a compounding AI system that becomes a definitive source of novel medicines that are more likely to succeed in clinical development than any prior technology.”

Sources

• Flagship Pioneering via PR Newswire: Flagship Pioneering Forms Etcelera to Move Drug Discovery from Probability to Prediction (Oct. 29, 2026)
• BioPharma Dive: Flagship blends three biotech startups to form Etcelera (Oct. 29, 2026)
• Fierce Biotech: Flagship brings 3 biotech platforms together to launch AI drug discovery player Etcelera (Oct. 29, 2026)
• FRED, Federal Reserve Bank of St. Louis: Unemployment Rate in Massachusetts (MAUR)